Court of Appeals for the Federal Circuit Upholds Written Description Requirement in Novartis vs. Torrent Pharma

In a significant decision, the Court of Appeals for the Federal Circuit upheld the district court's ruling that Novartis Pharmaceuticals Corporation's patent lacked an adequate written description, impacting the scope of patent protection for pharmaceutical compositions. This case, Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc., involved the patent for Entresto, a combination therapy of valsartan and sacubitril. The court's decision emphasized the importance of a patent's written description in defining its scope of protection, particularly for pharmaceutical compositions.

In the case, Novartis Pharmaceuticals Corporation challenged the district court's written description determination, arguing that the patent's claims were invalid for lack of written description. Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., and MSN Pharmaceuticals, Inc., MSN Laboratories Private Ltd., and MSN Life Sciences Private Ltd. settled their disputes with Novartis, leaving only MSN to participate in the appeal. The appeal focused on whether the claims of the '659 patent were invalid for lack of written description, non-enablement, or obviousness.

The '659 patent, which is set to expire on January 15, 2025, due to the grant of Patent Term Extension, describes a combination therapy of valsartan and sacubitril in a specific form known as a "complex." Valsartan is an angiotensin receptor blocker (ARB) that reduces blood-vessel constriction, while sacubitril is a neutral endopeptidase (NEP) inhibitor that also reduces blood vessel constriction through a different mechanism. The patent sought to combine these drugs to achieve a more efficacious treatment with fewer side effects.

The Federal Circuit reversed the district court's determination that the claims lacked an adequate written description. The court held that the patent's written description was sufficient to meet the requirements of 35 U.S.C. section 112(a). The court also affirmed the district court's determinations that the claims were not shown to be invalid as either non-enablement or obvious.

This decision highlights a clear and detailed written description in pharmaceutical patents. It highlights the need for patent applicants to provide comprehensive information about their inventions to ensure adequate protection under patent law. The outcome of this case will likely influence future patent applications and litigation in the pharmaceutical industry.